MedTrace Logo

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

NCT03185793 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2019-08-07

No results posted yet for this study

Summary

The objective of the study is to assess efficacy and safety of SHR4640 in subjects with hyperuricemia.

Conditions

  • Hyperuricemia

Interventions

DRUG

Placebo

Placebo once daily for 5 weeks

DRUG

SHR4640

1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks

DRUG

benzbromarone

25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chunde Bao · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2018-07-20
Completion
2018-07-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03185793 on ClinicalTrials.gov